Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax in CLL with 17p deletion
NCT01889186Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2013
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of venetoclax in chronic lymphocytic leukemia (CLL), sponsored by AbbVie Inc.. Started Jun 2013; status: completed.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01889186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01889186.